Literature DB >> 24007661

Identification of a primary biliary cirrhosis associated protein as lysosome-associated membrane protein-2.

Lu Wang1, Jingbo Wang, Yongquan Shi, Xinmin Zhou, Xuechang Wang, Zengshan Li, Xiaofeng Huang, Jianhong Wang, Zheyi Han, Tingting Li, Min Wang, Ruian Wang, Daiming Fan, Ying Han.   

Abstract

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown etiology and abnormality of hepatobiliary transport might contribute to its pathogenesis. In this study, we aimed to isolate and identify new molecules associated with PBC. With hepatocyte canalicular membrane vesicles (CMVs) of PBC patients as immunogens, we screened the monoclonal antibody 1F9 (mAb1F9), whose antigen dominantly recognized the subapical domains in hepatocytes in normal livers. Immunohistochemistry revealed that the expression of mAb1F9 antigen (mAb1F9-Ag) significantly increased in PBC livers compared with control groups including normal livers, cirrhosis or cholestasis other than PBC. Interestingly, the augmented expression of mAb1F9-Ag was correlated with the severity of PBC, and ursodeoxycholic acid treatment may significantly improve the recovery of mAb1F9-Ag. In addition, redistribution of mAb1F9-Ag was found in 46% of PBC. mAb1F9-Ag was isolated and analyzed with mass spectrometry, which indicated lysosome-associated membrane protein 2 (LAMP-2) as the candidate. Further studies showed that mAb1F9 recognized LAMP-2 immunoprecipitates and vice verse, mAb1F9 reacted with recombinant LAMP-2. mAb1F9 and LAMP-2 antibody exhibited similar staining pattern and displayed similar subcellular localization. Together, the identity of mAb1F9-Ag is LAMP-2, suggesting that LAMP-2 may assist in the differentiation of PBC and predict a poor outcome in patients with PBC. BIOLOGICAL SIGNIFICANCE: This manuscript describes the expression of a specific antibody, named mAb1F9. The antigen recognized by mAb1F9 may assist in the differentiation of primary biliary cirrhosis (PBC) and predict a poor outcome in patients with PBC. Through antigen identification, we confirm the identity of mAb1F9-Ag as lysosome-associated membrane protein 2 (LAMP-2). The clinical relevance of the manuscript is well regarded since markers are rare and usually not successful for PBC diagnosis and treatment.
© 2013.

Entities:  

Keywords:  4′,6-diamidino-2-phenylindole; AE2; AMA; BSEP; CMVs; Canalicular membrane vesicles (CMVs); DAPI; HBV; LAMP-1; LAMP-2; Lysosome-associated membrane protein 2 (LAMP-2); MALDI-TOF/TOF; MDR1; MDR3; MRP2; MS; Monoclonal antibody 1F9 (mAb1F9); PBC; PBS; PFIC2; PMF; Primary biliary cirrhosis (PBC); RT-PCR; SDS-PAGE; SS; Sjögren's syndrome; UDCA; anion exchanger 2; anti-mitochondria antibody; bile salt export pump; canalicular membrane vesicles; hepatitis B virus; lysosome-associated membrane protein 1; lysosome-associated membrane protein 2; mAb1F9; mAb1F9 antigen; mAb1F9-Ag; mass spectrometry; matrix assisted laser desorption/ionization-tandem time-of-flight analysis; monoclonal antibody 1F9; multidrug resistant protein 2; multiple drug resistant protein 1; multiple drug resistant protein 3; peptide mass fingerprinting; phosphate buffer saline; primary biliary cirrhosis; progressive familial intrahepatic cholestasis type 2; real-time polymerase chain reaction; sodium dodecyl sulfate-polyacrylamide gel electrophoresis; ursodeoxycholic acid

Mesh:

Substances:

Year:  2013        PMID: 24007661     DOI: 10.1016/j.jprot.2013.08.019

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  4 in total

1.  Sweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses.

Authors:  Qiao-Ling Yang; Fan Yang; Jun-Ting Gong; Xiao-Wen Tang; Guang-Yun Wang; Zheng-Tao Wang; Li Yang
Journal:  Acta Pharmacol Sin       Date:  2016-08-08       Impact factor: 6.150

2.  A Critical Evaluation of Liver Pathology in Humans with Danon Disease and Experimental Correlates in a Rat Model of LAMP-2 Deficiency.

Authors:  Lu Wang; Jingbo Wang; Weile Cai; Yongquan Shi; Xinmin Zhou; Guanya Guo; Changcun Guo; Xiaofeng Huang; Zheyi Han; Shuai Zhang; Shuoyi Ma; Xia Zhou; Daiming Fan; M Eric Gershwin; Ying Han
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 3.  A shift in paradigm towards human biology-based systems for cholestatic-liver diseases.

Authors:  Fozia Noor
Journal:  J Physiol       Date:  2015-11-04       Impact factor: 5.182

4.  A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis.

Authors:  Lu Wang; Guan-ya Guo; Jing-bo Wang; Xin-min Zhou; Qiong Yang; Zhe-yi Han; Qiang Li; Jing-wen Zhang; Yun Cai; Xiao-li Ren; Xia Zhou; Rui-Rui Chen; Yong-quan Shi; Ying Han; Dai-ming Fan
Journal:  Sci Rep       Date:  2015-04-20       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.